Table 2 Active clinical trials combining radiation with PD-1/PD-L1 targeted therapy
From: Current clinical trials testing the combination of immunotherapy with radiotherapy
NCT Number | Phase | Title | Conditions | RT Details | Enrollment | Sponsor/Collaborators |
|---|---|---|---|---|---|---|
NCT02642809 | Phase 0 | Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers | Esophageal Cancer | Hypofx brachytherapy | 15 | Washington University School of Medicine|Merck Sharp & Dohme Corp. |
NCT02463994 | Phase 0 | A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC | NSCLC | Hypofx RT | 12 | University of Michigan Cancer Center|University of Washington |
NCT02587455 | Phase 1 | Pembrolizumab and Palliative Radiotherapy in Lung | Thoracic Tumours | Palliative EBRT | 48 | Royal Marsden NHS Foundation Trust|Merck Sharp & Dohme Corp. |
NCT02608385 | Phase 1 | Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | NSCLC | SBRT, 3-5 fx | 138 | University of Chicago |
NCT02621398 | Phase 1 | Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB NSCLC | NSCLC | EBRT | 30 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI)|Merck Sharp & Dohme Corp. |
NCT02313272 | Phase 1 | Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas | Malignant Glioma | FSRT over 5Â days | 32 | H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme Corp. |
NCT02402920 | Phase 1 | Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer | Lung Cancer | EBRT, 1.5 Gy × 30 fx, BID | 80 | M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp. |
NCT02716948 | Phase 1 | Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine | Melanoma (Brain metastases) | SRS | 90 | Sidney Kimmel Comprehensive Cancer Center |
NCT02560636 | Phase 1 | Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer | Invasive Bladder Cancer | Hypofx RT | 34 | Royal Marsden NHS Foundation Trust|Merck Sharp & Dohme Corp. |
NCT02318771 | Phase 1 | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | Metastatic HN, RCC, Melanoma, Lung Cancer | EBRT | 40 | Thomas Jefferson University|Merck Sharp & Dohme Corp. |
NCT02648633 | Phase 1 | Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma | Glioblastoma | SRS | 17 | University of Virginia |
NCT02303366 | Phase 1 | Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475 | Oligometastatic Breast Cancer | SBRT, 20 Gy × 1 fx | 15 | Peter MacCallum Cancer Centre, Australia |
NCT02659540 | Phase 1 | A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma | Melanoma | 3 Gy × 10 fx, or 9 Gy × 3 fx | 18 | Ludwig Institute for Cancer Research|Bristol-Myers Squibb |
NCT02586207 | Phase 1 | Pembrolizumab in Combination With CRT for LA-SCCHN | Advanced HN Cancers | EBRT, 7 wks | 39 | Sanford Health|Merck Sharp & Dohme Corp. |
NCT02303990 | Phase 1 | RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers | Metastatic Cancers | Hypofx RT | 70 | Abramson Cancer Center of the University of Pennsylvania |
NCT02764593 | Phase 1 | Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma | Advanced HN Cancers | IMRT, 7 wks | 120 | RTOG Foundation, Inc.|Bristol-Myers Squibb |
NCT02400814 | Phase 1 | MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With NSCLC | NSCLC | SBRT, 5 fx | 45 | University of California, Davis|National Cancer Institute (NCI)|Genentech, Inc. |
NCT02383212 | Phase 1 | Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies | Advanced Cancer | Hypofx RT | 973 | Regeneron Pharmaceuticals|Sanofi |
NCT02311361 | Phase 1 | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | Pancreatic Cancer | SBRT, 1-5 fx | 60 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
NCT02696993 | Phase 1|Phase 2 | Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From NSCLC | Lung Cancer (Brain metastases) | WBRT 3 Gy × 10 fx, SRS 1 fx | 80 | M.D. Anderson Cancer Center|Bristol-Myers Squibb |
NCT02444741 | Phase 1|Phase 2 | MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With NSCLC (NSCLC) | Lung Cancer | EBRT or SBRT | 104 | M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp. |
NCT02530502 | Phase 1|Phase 2 | Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma | Glioblastoma | EBRT | 50 | Northwestern University|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI) |
NCT02730546 | Phase 1|Phase 2 | Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery | Gastric Cancer | EBRT | 68 | Mayo Clinic|National Cancer Institute (NCI) |
NCT02759575 | Phase 1|Phase 2 | A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma | Advanced HN Cancers | EBRT | 47 | Nooshin Hashemi-Sadraei|Merck Sharp & Dohme Corp.|University of Cincinnati |
NCT02407171 | Phase 1|Phase 2 | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | Melanoma, Lung Cancer | SBRT, 1-5 fx | 60 | Yale University |
NCT02735239 | Phase 1|Phase 2 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer | Esophageal Cancer | EBRT | 75 | Ludwig Institute for Cancer Research|AstraZeneca |
NCT02305186 | Phase 1|Phase 2 | Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer | Pancreatic Cancer | EBRT, 1.8 Gy × 28 fx | 56 | Osama Rahma, MD|M.D. Anderson Cancer Center|University of Virginia |
NCT02599779 | Phase 2 | A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients | Metastatic RCC | SBRT | 35 | Sunnybrook Health Sciences Centre|Merck Sharp & Dohme Corp.|Ozmosis Research Inc. |
NCT02648282 | Phase 2 | Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer | Pancreatic Cancer | SBRT, 3-5 fx | 54 | Sidney Kimmel Comprehensive Cancer Center|Merck Sharp & Dohme Corp. |
NCT02492568 | Phase 2 | Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC | NSCLC | SBRT, 8 Gy × 3 fx | 74 | The Netherlands Cancer Institute|Merck Sharp & Dohme Corp. |
NCT02641093 | Phase 2 | Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma | HN Cancer | EBRT, 6 wks | 80 | Trisha Wise-Draper|Merck Sharp & Dohme Corp.|University of Cincinnati |
NCT02684253 | Phase 2 | Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | HN Cancer | SBRT, 9Â Gy x 3 fx | 40 | Memorial Sloan Kettering Cancer Center|University of Chicago |
NCT02667587 | Phase 2 | Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer). | Glioblastoma | EBRT | 320 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |
NCT02437071 | Phase 2 | Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients | Metastatic Colorectal Cancer | EBRT vs radiofrequency ablation | 48 | Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp. |
NCT02658097 | Phase 2 | A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC | Stage IV NSCLC | 8 Gy × 1 fx | 66 | Case Comprehensive Cancer Center |
NCT02562625 | Phase 2 | Trial of Pembrolizumab and Radiotherapy in Melanoma | Melanoma | 8 Gy × 3 fx | 234 | Royal Marsden NHS Foundation Trust|University of Manchester|University of Leeds |
NCT02730130 | Phase 2 | Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients | Metastatic Breast Cancer | EBRT | 17 | Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp. |
NCT02707588 | Phase 2 | Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC | Advanced HN Cancers | EBRT | 114 | Groupe Oncologie Radiotherapie Tete et Cou |
NCT02621151 | Phase 2 | Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder | Muscle-invasive Urothelial Cancer of the Bladder | Hypofx RT | 54 | New York University School of Medicine|Merck Sharp & Dohme Corp. |
NCT02609503 | Phase 2 | Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin | Head and Neck Cancer | IMRT, 7 wks | 29 | UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp. |
NCT02677155 | Phase 2 | Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma | Follicular Lymphoma | 8 Gy × 1 fx | 20 | Oslo University Hospital|Norwegian Cancer Society|Merck Sharp & Dohme Corp. |
NCT02586610 | Phase 2 | Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer | Rectal Cancer | EBRT, 1.8 Gy × 28 fx | 53 | Osama Rahma, MD|Hoosier Cancer Research Network|Merck Sharp & Dohme Corp. |
NCT02434081 | Phase 2 | NIvolumab COnsolidation After Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B NSCLC | NSCLC | EBRT | 43 | European Thoracic Oncology Platform|Bristol-Myers Squibb|Frontier Science Foundation, Hellas |
NCT02296684 | Phase 2 | Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma | HN Cancer | IMRT, 6 wks | 46 | Washington University School of Medicine|Merck Sharp & Dohme Corp. |
NCT02499367 | Phase 2 | Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients | Breast Cancer | 20 Gy × 1, or 8 Gy × 3 | 84 | The Netherlands Cancer Institute|Bristol-Myers Squibb |
NCT02635360 | Phase 2 | Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer | Cervical Cancer | EBRT + brachytherapy | 88 | Linda R Duska|Merck Sharp & Dohme Corp.|University of Virginia |
NCT02662062 | Phase 2 | Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer | Bladder Cancer | EBRT, 6 wks | 30 | Australian and New Zealand Urogenital and Prostate Cancer Trials Group |
NCT02336165 | Phase 2 | Phase 2 Study of MEDI4736 in Patients With Glioblastoma | Glioblastoma | EBRT | 108 | Ludwig Institute for Cancer Research|MedImmune LLC |
NCT02289209 | Phase 2 | Reirradiation With MK-3475 (Pembrolizumab) in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck | Recurrent HN Cancers | EBRT | 48 | Dan Zandberg|Merck Sharp & Dohme Corp.|University of Maryland |
NCT02768558 | Phase 3 | Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC | NSCLC | EBRT (IMRT or 3D CRT) | 660 | RTOG Foundation, Inc.|Bristol-Myers Squibb |
NCT02617589 | Phase 3 | Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) | Brain Cancer | EBRT | 550 | Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd |